



SEQUENCE LISTING

<110> SHEFFIELD, VAL C.
ALWARD, WALLACE L.M.
STONE, EDWIN M.
NISHIMURA, DARRYL
PATIL, SHIVA

<120> THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART
DISEASE BASED ON A NOVEL HUMAN TRANSCRIPTION FACTOR

<130> IOWA:042USD1

<140> 09/612,809

<141> 2000-07-10

<160> 20

<170> PatentIn Ver. 2.1

<210> 1
<211> 2284
<212> DNA
<213> Homo sapiens

<400> 1
cgagaaaagg tgacgcgggg cccgggcagg cggccggcgc gcggcccccc ccccccccgc 60
cctggttatt tggccgcctt cgccggcaga tcagggcaga gtctcctgga aggcgcaggc 120
agtgtggcga gaagggcgcc tgcttgttct ttcttttgat ctgctttccc ccgttgcgc 180
ctggaaagctg cgccgcgagt tcctgcaagg cggctgcgc cggccggggcc cggccttc 240
ccctcgcaga gacccgcct cgccggcgc cggcccccga gtagccca ggcgcggag 300
gagccagccc cagcagcgc cgggagaggc ggcagcgcag cggacgcac agcgcagcgg 360
gccggcacca gctggccgg gcccggactc ggactcggcg gccggcgccg cgcggcccgg 420
cccgagcgg ggtggggggc ggcgggcccgc gcggggcggc ggcgagcggg ggcccacacc 480
ctcaaagccg aactaaatcg aaccccaaag caggaaaagc taaaggAACCC catcaaggca 540
aaatcgaaac taaaaaaaaaa aaatccaatt aaaaaaaaaacc cctgagaata ttcaccacac 600
cagcgaacag aatatccctc caaaaattca gtcaccaggc accagcacga agaaaaactct 660
attttcttaa ccgattaatt cagagccacc tccactttgc cttgtctaaa taaacaaacc 720
cgtaaactgt tttatacaga gacagaaaaa tcttggttta taaaggaca gtgttactcc 780
agataaacacg taagtttctt cttgttttc agagacctgc tttccctcc tccctctcc 840
cctctcttc cttcttcctt gcctctcacc tgtaagatat tattttatcc tatgttgaag 900
ggagggggaa agtccccgtt tatgaaaatgc gcttttttattcatgaa cttgtttaa 960
aatgtaaatt gcaacatagt aatttatttt taattttagt ttggatgtcg tggaccaaac 1020
gccagaaaagt gttccaaaaa cctgacgtta aattgcctga aactttaat tgtgttttt 1080
ttctcattat aaaaaggaa actgtattaa tcttattcta tcctctttc tttcttttg 1140
ttgaacatata tcattgtttg tttattaata aattaccatt cagttgaat gagacctata 1200
tgtctggata cttaataga gcttaatatta ttacgaaaaa agatttcaga gataaaacac 1260
tagaagttac ctattctcca cctaaatctc tgaaaaatgg agaaaccctc tgacttagtcc 1320

atgtcaaatt ttactaaaag tcttttggtagatttattt ttcctgcagc atcttctgca 1380
aaatgtacta tatagtccgc ttgcttgag gctagtaaaa agatatttt ctaaacagat 1440
tggagttggc atataaacaat acacgtttc tcactaatga cagtccatga ttccggaaatt 1500
ttaagcccat gaatcagccg cggtcttacc acgggtgatgc ctgtgtgccg agagatggga 1560
ctgtgcggcc agatatgcac agataaataat ttggcttgc tattccatat aaaattgcag 1620
tgcatttat acatcccgtg gagccagatg ctgaatagat ttttcctat tatttcagtc 1680
ctttataaaaa ggaaaaataa accagtttt aaatgtatgt atataattct cccccattta 1740
caatccttca tgtattacat agaaggatg ctttttaaa aatatactgc ggggtggaaa 1800
gggatattta atctttgaga aactattta gaaaatatgt ttgttagaaca attatttttg 1860
aaaaagattt aaagcaataa caagaaggaa ggcgagagga gcagaacatt ttggcttagg 1920
gtggtttctt tttaaaccat ttttcttgc taatttacag ttaaacctag gggacaatcc 1980
ggattggccc tccccctttt gtaaataacc cagggaaatgt aataaattca ttatcttagg 2040
gtgatctgcc ctgccaatca gactttgggg agatggcgat ttgattacag acgttcgggg 2100
gggtgggggg cttgcagttt gttttggaga taatacagtt tcctgctatc tgccgctcct 2160
atctagaggc aacacttaag cagtaattgc tgttgcttgc tgtcaaaatt tgatcattgt 2220
taaaggattt ctgcaaataa atacacttta atttcagtc aaaaaaaaaa aaaaaaaaaa 2280
aaaa 2284

<210> 2

<211> 553

<212> PRT

<213> Homo sapiens

<400> 2

Met Gln Ala Arg Tyr Ser Val Ser Ser Pro Asn Ser Leu Gly Val Val
1 5 10 15

Pro Tyr Leu Gly Gly Glu Gln Ser Tyr Tyr Arg Ala Ala Ala Ala
20 25 30

Ala Gly Gly Gly Tyr Thr Ala Met Pro Ala Pro Met Ser Val Tyr Ser
35 40 45

His Pro Ala His Ala Glu Gln Tyr Pro Gly Gly Met Ala Arg Ala Tyr
50 55 60

Gly Pro Tyr Thr Pro Gln Pro Gln Pro Lys Asp Met Val Lys Pro Pro
65 70 75 80

Tyr Ser Tyr Ile Ala Leu Ile Thr Met Ala Ile Gln Asn Ala Pro Asp
85 90 95

Lys Lys Ile Thr Leu Asn Gly Ile Tyr Gln Phe Ile Met Asp Arg Phe
100 105 110

Pro Phe Tyr Arg Asp Asn Lys Gln Gly Trp Gln Asn Ser Ile Arg His
115 120 125

Asn Leu Ser Leu Asn Glu Cys Phe Val Lys Val Pro Arg Asp Asp Lys
130 135 140

Lys Pro Gly Lys Gly Ser Tyr Trp Thr Leu Asp Pro Asp Ser Tyr Asn
145 150 155 160

Met Phe Glu Asn Gly Ser Phe Leu Arg Arg Arg Arg Phe Lys Lys
165 170 175

Lys Asp Ala Val Lys Asp Lys Glu Glu Lys Asp Arg Leu His Leu Lys
180 185 190

Glu Pro Pro Pro Pro Gly Arg Gln Pro Pro Pro Ala Pro Pro Glu Gln
195 200 205

Ala Asp Gly Asn Ala Pro Gly Pro Gln Pro Pro Pro Val Arg Ile Gln
210 215 220

Asp Ile Lys Thr Glu Asn Gly Thr Cys Pro Ser Pro Pro Gln Pro Leu
225 230 235 240

Ser Pro Ala Ala Ala Leu Gly Ser Gly Ser Ala Ala Ala Val Pro Lys
245 250 255

Ile Glu Ser Pro Asp Ser Ser Ser Ser Leu Ser Ser Gly Ser Ser
260 265 270

Pro Pro Gly Ser Leu Pro Ser Ala Arg Pro Leu Ser Leu Asp Gly Ala
275 280 285

Asp Ser Ala Pro Pro Pro Ala Pro Ser Ala Pro Pro Pro His His
290 295 300

Ser Gln Gly Phe Ser Val Asp Asn Ile Met Thr Ser Leu Arg Gly Ser
305 310 315 320

Pro Gln Ser Ala Ala Ala Glu Leu Ser Ser Gly Leu Leu Ala Ser Ala
325 330 335

Ala Ala Ser Ser Arg Ala Gly Ile Ala Pro Pro Leu Ala Leu Gly Ala
340 345 350

Tyr Ser Pro Gly Gln Ser Ser Leu Tyr Ser Ser Pro Cys Ser Gln Thr
355 360 365

Ser Ser Ala Gly Ser Ser Gly Gly Gly Gly Ala Gly Ala Ala
370 375 380

Gly Gly Ala Gly Gly Ala Gly Thr Tyr His Cys Asn Leu Gln Ala Met
385 390 395 400

Ser Leu Tyr Ala Ala Gly Glu Arg Gly Gly His Leu Gln Gly Ala Pro
405 410 415

Gly Gly Ala Gly Gly Ser Ala Val Asp Asn Pro Leu Pro Asp Tyr Ser
420 425 430

Leu Pro Pro Val Thr Ser Ser Ser Ser Ser Leu Ser His Gly Gly
435 440 445

Gly Gly Gly Gly Gly Gly Gln Glu Ala Gly His His Pro Ala
450 455 460

Ala His Gln Gly Arg Leu Thr Ser Trp Tyr Leu Asn Gln Ala Gly Gly
465 470 475 480

Asp Leu Gly His Leu Ala Ser Ala Ala Ala Ala Ala Ala Gly
485 490 495

Tyr Pro Gly Gln Gln Asn Phe His Ser Val Arg Glu Met Phe Glu
500 505 510

Ser Gln Arg Ile Gly Leu Asn Asn Ser Pro Val Asn Gly Asn Ser Ser
515 520 525

Cys Gln Met Ala Phe Pro Ser Ser Gln Ser Leu Tyr Arg Thr Ser Gly
530 535 540

Ala Phe Val Tyr Asp Cys Ser Lys Phe
545 550

<210> 3
<211> 1662
<212> DNA
<213> Homo sapiens

<400> 3
atgcaggcgc gctactccgt gtccagcccc aactccctgg gagtggtgcc ctaccccg 60
ggcgagcaga gctactaccg cgcggcggcc gcggcgccg gggcgcccta caccggcatg 120
ccggccccca tgagcgtgta ctcgcaccct gcgcacgccc agcagtaccc gggcgccatg 180
cccccgccct acgggcccata cacgcccag ccgcagccca aggacatggt gaagccgccc 240
tatagctaca tcgcgctcat caccatggcc atccagaacg cccccggacaa gaagatcacc 300
ctgaacggca tctaccagtt catcatggac cgctccccct tctaccggaa caacaaggcag 360
ggctggcaga acagcatccg ccacaacctc tcgctcaacg agtgcttcgt caaggtgccg 420

cgcgacgaca agaagccggg caagggcagc tactggacgc tggacccgga ctccataaac 480
atgttcgaga acggcagctt cctgcggcg cgccggcgct tcaagaagaa ggacgcggtg 540
aaggacaagg aggagaagga caggctgcac ctcaaggagc cgccccggcc cggccggccag 600
cccccgcccc cgccgcccga gcaggccgac ggcaacgcgc ccgggccgca gccggccccc 660
gtgcgcatcc aggacatcaa gaccgagaac ggtacgtgcc cctcgccgcc ccagccccctg 720
tccccggccg ccgcctggg cagcggcagc gccggccggg tgcccaagat cgagagcccc 780
gacagcagca gcagcagcct gtccagcggg agcagcccc cgggcagcct gccgtcggcg 840
cggccgcetca gcctggacgg tgccggattcc ggcgcgcgc cgcgcgcgc ctcgcgcgc 900
ccgcccgcacc atagccaggg cttcagcgtg gacaacatca tgacgtcgct gcgggggtcg 960
ccgcagagcg cggccgcgg gctcagctcc ggccttctgg cctcgccggc cgcgtcctcg 1020
cgcgccgggta tcgcacccccc gctggcgtc ggcgcctact cgcgcggcca gagctccctc 1080
tacagctccc cctgcagcca gacctccagc gcgggcagct cgggcggcg cggccggcgc 1140
gcggggggccg cggggggcgc gggccgcgc gggacctacc actgcaacct gcaagccatg 1200
agcctgtacg cggccggcga gcgcggggc cacttgcagg gcgcgcgcgg gggcgcgggc 1260
ggctcggccg tggacaaccc cctgcccac tactctctgc ctccggtcac cagcagcagc 1320
tcgtcgctcc tgagtacgg cggccggccg ggcggccggc ggggaggcca ggaggccggc 1380
caccaccctg cggcccacca aggccgcctc acctcgttgtt acctgaacca ggcggccgga 1440
gacctgggcc acttggcaag cgcggccggc gcggccggcg cgcaggcta cccggccag 1500
cagcagaact tccactcggt gcgggagatg ttcaagtac agaggatcgg ttgaacaac 1560
tctccagtga acggaaatag tagctgtcaa atggccttcc ctccagcca gtctctgtac 1620
cgcacgtccg gagcttcgtt ctacgactgtt agcaagttt ga 1662

<210> 4
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 4
Pro Lys Asp Met Val Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Thr
1 5 10 15

Met Ala Ile Gln Asn Ala Pro Asp Lys Lys Ile Thr Leu Asn Gly Ile
20 25 30

Tyr Gln Phe Ile Met Asp Arg Phe Pro Phe Tyr Arg Asp Asn Lys Gln
35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Glu Cys Phe
50 55 60

Val Lys Val Pro Arg Asp Asp Lys Lys Pro Gly Lys Gly Ser Tyr Trp
65 70 75 80

Thr Leu Asp Pro Asp Ser Tyr Asn Met Phe Glu Asn Gly Ser Phe Leu
85 90 95

Arg Arg Arg Arg Arg Phe Lys Lys Lys Asp
100 105

<210> 5
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 5
Pro Lys Asp Leu Val Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Thr
1 5 10 15

Met Ala Ile Gln Asn Ala Pro Glu Lys Lys Ile Thr Leu Asn Gly Ile
20 25 30

Tyr Gln Phe Ile Met Asp Arg Phe Pro Phe Tyr Arg Glu Asn Lys Gln
35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Glu Cys Phe
50 55 60

Val Lys Val Pro Arg Asp Asp Lys Lys Pro Gly Lys Gly Ser Tyr Trp
65 70 75 80

Thr Leu Asp Pro Asp Ser Tyr Asn Met Phe Glu Asn Gly Ser Phe Leu
85 90 95

Arg Arg Arg Arg Arg Phe Lys Lys Lys Asp
100 105

<210> 6
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 6

Thr Thr Glu Pro Thr Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Ala
1 5 10 15

Met Ala Ile Gln Ser Ser Pro Gly Gln Arg Ala Thr Leu Ser Gly Ile
20 25 30

Tyr Arg Val Ile Met Gly Arg Phe Ala Phe Tyr Arg His Asn Arg Pro
35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Glu Cys Phe
50 55 60

Val Lys Val Pro Arg Asp Asp Arg Lys Pro Gly Lys Gly Ser Tyr Trp
65 70 75 80

Thr Leu Asp Pro Asp Cys His Asp Met Phe Glu His Gly Ser Phe Leu
85 90 95

Arg Arg Arg Arg Arg Phe Thr Arg Gln Thr
100 105

<210> 7

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 7

Ala Glu Thr Pro Gln Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Ala
1 5 10 15

Met Ala Ile Gln Asp Ala Pro Glu Gln Arg Val Thr Leu Asn Gly Ile
20 25 30

Tyr Gln Phe Ile Met Asp Arg Phe Pro Phe Tyr His Asp Asn Arg Gln
35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe
50 55 60

Val Lys Val Pro Arg Glu Lys Gly Arg Pro Gly Lys Gly Ser Tyr Trp
65 70 75 80

Thr Leu Asp Pro Arg Cys Leu Asp Met Phe Glu Asn Gly Asn Tyr Arg
85 90 95

Arg Arg Lys Arg Lys Pro Lys Pro Gly Pro
100 105

RECEIVED

<210> 8

OCT 31 2002

<211> 106

<212> PRT

<213> Artificial Sequence

TECH CENTER 1600/2900

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 8

Pro Leu Gln Arg Gly Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Ala
1 5 10 15

Met Ala Leu Ala His Ala Pro Gly Arg Arg Leu Thr Leu Ala Ala Ile
20 25 30

Tyr Arg Phe Ile Thr Glu Arg Phe Ala Phe Tyr Arg Asp Ser Pro Arg
35 40 45

Lys Trp Gln Asn Ser Ile Arg His Asn Leu Thr Leu Asn Asp Cys Phe
50 55 60

Val Lys Val Pro Arg Glu Pro Gly Asn Pro Gly Lys Gly Asn Tyr Trp
65 70 75 80

Thr Leu Asp Pro Ala Ala Ala Asp Met Phe Asp Asn Gly Ser Phe Leu
85 90 95

Pro Arg Arg Lys Arg Phe Lys Arg Ala Glu
100 105

<210> 9

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 9

Pro Leu Gln Arg Gly Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Ala
1 5 10 15

Met Ala Ile Ala His Ala Pro Glu Arg Arg Leu Thr Leu Gly Gly Ile
20 25 30

Tyr Lys Phe Ile Thr Glu Arg Phe Pro Phe Tyr Arg Asp Asn Pro Lys
35 40 45

Lys Trp Gln Asn Ser Ile Arg His Asn Leu Thr Leu Asn Asp Cys Phe
50 55 60

Leu Lys Ile Pro Arg Glu Ala Gly Arg Pro Gly Lys Gly Asn Tyr Trp
65 70 75 80

Ala Leu Asp Pro Asn Ala Glu Asp Met Phe Glu Ser Gly Ser Phe Leu
85 90 95

Arg Arg Arg Lys Arg Phe Lys Arg Ser Asp
100 105

<210> 10

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 10

Ala Arg Gln Pro Ala Lys Pro Pro Ser Ser Tyr Ile Ala Leu Ile Thr
1 5 10 15

Met Ala Ile Leu Gln Ser Pro His Lys Arg Leu Thr Leu Ser Gly Ile
20 25 30

Cys Ala Phe Ile Ser Asp Arg Phe Pro Tyr Tyr Arg Arg Lys Glu Pro
35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe
50 55 60

Val Lys Ile Pro Arg Glu Pro Gly Arg Pro Gly Lys Gly Asn Tyr Trp
65 70 75 80

Ser Leu Asp Pro Ala Ser Gln Asp Met Phe Asp Asn Gly Ser Phe Leu
85 90 95

Arg Arg Arg Lys Arg Phe Gln Arg Asn Gln
100 105

<210> 11
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 11
Arg Thr Arg Leu Val Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Thr
1 5 10 15

Met Ala Ile Leu Gln Ser Pro Lys Lys Arg Leu Thr Leu Ser Glu Ile
20 25 30

Cys Glu Phe Ile Ser Gly Arg Phe Pro Tyr Tyr Arg Glu Lys Phe Pro
35 40 45

Ala Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe
50 55 60

Val Lys Ile Pro Arg Glu Pro Gly Asn Pro Gly Lys Gly Asn Tyr Trp
65 70 75 80

Thr Leu Asp Pro Glu Ser Ala Asp Met Phe Asp Asn Gly Ser Phe Leu
85 90 95

Arg Arg Arg Lys Arg Phe Lys Arg Gln Pro
100 105

<210> 12
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 12

Arg Ser Pro Leu Val Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Thr
1 5 10 15

Met Ala Ile Leu Gln Ser Pro Lys Lys Arg Leu Thr Leu Ser Glu Ile
20 25 30

Cys Glu Phe Ile Ser Gly Arg Phe Pro Tyr Tyr Arg Glu Lys Phe Pro
35 40 45

Ala Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe
50 55 60

Val Lys Ile Pro Arg Glu Pro Gly Asn Pro Gly Lys Gly Asn Tyr Trp
65 70 75 80

Thr Leu Asp Pro Glu Ser Ala Asp Met Phe Asp Asn Gly Ser Phe Leu
85 90 95

Arg Arg Lys Arg Arg Phe Lys Arg Gln Pro
100 105

<210> 13

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 13

Ile Arg Arg Pro Glu Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Val
1 5 10 15

Met Ala Ile Gln Ser Ser Pro Thr Lys Arg Leu Thr Leu Ser Glu Ile
20 25 30

Tyr Gln Phe Leu Gln Ser Arg Phe Pro Phe Phe Arg Gly Ser Tyr Gln
35 40 45

Gly Trp Lys Asn Ser Val Arg His Asn Leu Ser Leu Asn Glu Cys Phe
50 55 60

Ile Lys Leu Pro Lys Gly Leu Gly Arg Pro Gly Lys Gly His Tyr Trp
65 70 75 80

Thr Ile Asp Pro Ala Ser Glu Phe Met Phe Glu Asn Gly Ser Phe Arg
85 90 95

Arg Arg Arg Arg Gly Phe Arg Arg Lys Cys
100 105

<210> 14
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 14
Leu Arg Arg Pro Glu Lys Pro Pro Tyr Ser Tyr Ile Ala Leu Ile Val
1 5 10 15

Met Ala Ile Gln Ser Ser Pro Ser Lys Arg Leu Thr Leu Ser Glu Ile
20 25 30

Tyr Gln Phe Leu Gln Ala Arg Phe Pro Phe Phe Arg Gly Ala Tyr Gln
35 40 45

Gly Trp Lys Asn Ser Val Arg His Asn Leu Ser Leu Asn Glu Cys Phe
50 55 60

Ile Lys Leu Pro Lys Gly Leu Gly Arg Pro Gly Lys Gly His Tyr Trp
65 70 75 80

Thr Ile Asp Pro Ala Ser Glu Phe Met Phe Glu Asn Gly Ser Phe Arg
85 90 95

Arg Arg Arg Arg Gly Phe Arg Arg Lys Cys
100 105

<210> 15
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 15
Asn Gly Lys Tyr Glu Lys Pro Pro Phe Ser Tyr Asn Ala Leu Ile Met
1 5 10 15

Met Ala Ile Arg Gln Ser Pro Glu Lys Arg Leu Thr Leu Asn Gly Ile
20 25 30

Tyr Glu Phe Ile Met Lys Asn Phe Pro Tyr Tyr Arg Glu Asn Lys Gln
35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Lys Cys Phe
50 55 60

Val Lys Val Pro Arg His Tyr Asp Asp Pro Gly Lys Gly Asn Tyr Trp
65 70 75 80

Met Leu Asp Pro Ser Ser Tyr Asp Asp Val Ile Gly Gly Thr Thr Gly
85 90 95

Lys Leu Arg Arg Arg Ser Thr Thr Ser Pro
100 105

<210> 16
<211> 106
<212> PRT
<213> Artificial Sequence

<400> 16
Asn Gly Lys Tyr Glu Lys Pro Pro Phe Ser Tyr Asn Ala Leu Ile Met
1 5 10 15

Met Ala Met Arg Gln Ser Pro Glu Lys Arg Leu Thr Leu Asn Gly Ile
20 25 30

Tyr Glu Phe Ile Met Lys Asn Phe Pro Tyr Tyr Arg Glu Asn Lys Gln
35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Lys Cys Phe
50 55 60

Val Lys Val Pro Arg His Tyr Asp Asp Pro Gly Lys Gly Asn Tyr Trp
65 70 75 80

Met Leu Asp Pro Ser Ser Tyr Asp Asp Val Ile Gly Gly Thr Thr Gly
85 90 95

Lys Leu Arg Arg Ser Thr Thr Ser Pro Ala

100

105

<210> 17
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 17
Gly Lys Tyr Glu Lys Pro Pro Pro Phe Ser Tyr Asn Ala Leu Ile Met
1 5 10 15

Met Ala Ile Arg Gln Ser Pro Glu Lys Arg Leu Thr Leu Asn Gly Ile
20 25 30

Tyr Glu Phe Ile Met Lys Asn Phe Pro Tyr Tyr Arg Glu Asn Lys Gln
35 40 45

Gly Trp His Asn Ser Ile Arg Asp Asn Leu Ser Leu Asn Lys Cys Phe
50 55 60

Val Lys Val Pro Arg His Tyr Asp Asp Pro Gly Lys Gly Asn Tyr Trp
65 70 75 80

Met Leu Asp Pro Ser Ser Asp Asp Val Phe Ile Gly Gly Thr Thr Gly
85 90 95

Lys Leu Arg Arg Ser Thr Thr Ser Arg
100 105

<210> 18
<211> 76
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 18
Leu Met Lys Leu Val Arg Pro Pro Tyr Ser Tyr Ser Ala Leu Ile Ala
1 5 10 15

Met Ala Ile His Gly Ala Pro Asp Lys Arg Leu Thr Leu Ser Gln Ile
20 25 30

Tyr Gln Tyr Val Ala Asp Asn Phe Pro Phe Tyr Asn Lys Ser Lys Ala
35 40 45

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Asp Cys Phe
50 55 60

Lys Lys Val Pro Arg Asp Glu Asp Asp Pro Gly Lys
65 70 75

<210> 19

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 19
Thr Asn Pro His Val Lys Pro Pro Tyr Ser Tyr Ala Thr Leu Ile Cys
1 5 10 15

Met Ala Met Gln Ala Ser Lys Ala Thr Lys Ile Thr Leu Ser Ala Ile
20 25 30

Tyr Lys Trp Ile Thr Asp Asn Phe Cys Tyr Phe Arg His Ala Asp Pro
35 40 45

Thr Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Lys Cys Phe
50 55 60

Ile Lys Val Pro Arg Glu Lys Asp Glu Pro Gly Lys Gly Phe Trp
65 70 75 80

Arg Ile Asp Pro Gln Tyr Ala Glu Arg Leu Leu Ser Gly Ala Phe Lys
85 90 95

Lys Arg Arg Leu Pro Phe Val His Ile His
100 105

<210> 20

<211> 98

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 20

Trp Gly Asn Leu Ser Tyr Ala Asp Leu Ile Thr Lys Ala Ile Glu Ser
1 5 10 15

Ser Ala Glu Lys Arg Leu Thr Leu Ser Gln Ile Tyr Glu Trp Met Val
20 25 30

Lys Ser Val Pro Tyr Phe Lys Asp Lys Gly Asp Ser Asn Ser Ser Ala
35 40 45

Gly Trp Gln Lys Ser Ile Arg His Asn Leu Ser Leu His Ser Lys Phe
50 55 60

Ile Arg Val Gln Asn Glu Gly Thr Gly Lys Ser Ser Trp Trp Met Leu
65 70 75 80

Asn Pro Glu Gly Lys Ser Gly Lys Ser Pro Arg Arg Ala Ala Ser
85 90 95

Met Asp